Search Result

Results for "

hypoglycemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (6) Bacterial (6) Biochemical Assay Reagents (1) Dipeptidyl Peptidase (1) DYRK (1) Endogenous Metabolite (2) GCGR (1) GLP Receptor (2) Glucokinase (1) Insulin Receptor (1) Potassium Channel (3) Somatostatin Receptor (4) Topoisomerase (6)
By Research Areas:	Cardiovascular Disease (3) Endocrinology (5) Infection (6) Inflammation/Immunology (2) Metabolic Disease (16)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N3015

Bruceine E	Others	Metabolic Disease
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

HY-P0264

Exendin(9-39) amide Maximum Cited Publications 25 Publications Verification Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-121965

β-D-Glucose	Biochemical Assay Reagents Endogenous Metabolite	Others
β-D-Glucose, also known as glucose, is a monosaccharide, the most important carbohydrate in biological systems, the main energy source of cells, and plays a key role in various metabolic processes. β-D-Glucose has unique chemical properties that make it an abundant component in plant and animal tissues and is readily metabolized by organisms to produce cellular energy. It is commonly used to improve hypoglycemia and dehydration, and as a sweetener and preservative in food and beverage production.

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-P3469

Dasiglucagon	GCGR	Metabolic Disease
Dasiglucagon is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .

HY-P0264A

Exendin(9-39) amide acetate Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

HY-115014

Cibenzoline succinate Cifenline succinate; Ro 22-7796 succinate	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC₅₀ of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities .

HY-123171

ASP8497	Dipeptidyl Peptidase	Metabolic Disease
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .

HY-159496

Dyrk1A-IN-10	DYRK	Metabolic Disease
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .

HY-125316

AMG-151 ARRY-403	Endogenous Metabolite	Metabolic Disease
AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .

HY-106577R

Cibenzoline (Standard)	Potassium Channel	Cardiovascular Disease Metabolic Disease
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-15675

AZD1656	Glucokinase	Metabolic Disease
AZD1656 is a potent, selective and orally active glucokinase activator with an EC₅₀ of 60 nM. AZD1656 has the potential for type 2 diabetes research .

HY-114191

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-114191A

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-10581

Gatifloxacin 4 Publications Verification AM-1155; BMS-206584; PD135432	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis?in vivo.

HY-10581A

Gatifloxacin hydrochloride 4 Publications Verification AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-10581B

Gatifloxacin mesylate AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

HY-10581C

Gatifloxacin sesquihydrate AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.

HY-10581R

Gatifloxacin (Standard)	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.

HY-10581CR

Gatifloxacin (sesquihydrate) (Standard)	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.

Cat. No.	Product Name	Type

HY-121965

β-D-Glucose	Carbohydrates
β-D-Glucose, also known as glucose, is a monosaccharide, the most important carbohydrate in biological systems, the main energy source of cells, and plays a key role in various metabolic processes. β-D-Glucose has unique chemical properties that make it an abundant component in plant and animal tissues and is readily metabolized by organisms to produce cellular energy. It is commonly used to improve hypoglycemia and dehydration, and as a sweetener and preservative in food and beverage production.

β-D-Glucose

Carbohydrates

β-D-Glucose, also known as glucose, is a monosaccharide, the most important carbohydrate in biological systems, the main energy source of cells, and plays a key role in various metabolic processes. β-D-Glucose has unique chemical properties that make it an abundant component in plant and animal tissues and is readily metabolized by organisms to produce cellular energy. It is commonly used to improve hypoglycemia and dehydration, and as a sweetener and preservative in food and beverage production.

Cat. No.	Product Name	Target	Research Area

HY-P3469A

Dasiglucagon acetate	Peptides	Metabolic Disease
Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .

HY-P0264

Exendin(9-39) amide 20+ Cited Publications Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-P3469

Dasiglucagon	GCGR	Metabolic Disease
Dasiglucagon is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research .

HY-P3056

GHRF, ovine	Peptides	Endocrinology
GHRF, ovine is a growth hormone-releasing factor. GHRF is a specific mediator for the effects of hypoglycemia upon the release of pituitary growth hormone (GH) .

HY-P0264A

Exendin(9-39) amide acetate Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

Bruceine E	Structural Classification Simaroubaceae Classification of Application Fields Terpenoids Source classification Metabolic Disease Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr.	Others
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

β-D-Glucose	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Biochemical Assay Reagents Endogenous Metabolite
β-D-Glucose, also known as glucose, is a monosaccharide, the most important carbohydrate in biological systems, the main energy source of cells, and plays a key role in various metabolic processes. β-D-Glucose has unique chemical properties that make it an abundant component in plant and animal tissues and is readily metabolized by organisms to produce cellular energy. It is commonly used to improve hypoglycemia and dehydration, and as a sweetener and preservative in food and beverage production.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks